Drug Development and Regulation Indian Medical PG Practice Questions and MCQs
Practice Indian Medical PG questions for Drug Development and Regulation. These multiple choice questions (MCQs) cover important concepts and help you prepare for your exams.
Drug Development and Regulation Indian Medical PG Question 1: According to which of the following guidelines must a registered medical practitioner preserve medical records of patients for a minimum of 3 years from the last date of treatment?
- A. Medical Council of India Act: Professional misconduct and medical ethics (Correct Answer)
- B. Indian Medical Council (Professional Conduct) Regulations: Medical certificate guidelines
- C. Consumer Protection Act: Medical services as consumer services
- D. Section 304A IPC: Death caused by negligence (medical negligence)
Drug Development and Regulation Explanation: ***Medical Council of India Act: Professional misconduct and medical ethics***
- The **Professional Conduct, Etiquette, and Ethics Regulations, 2002**, issued under the **Medical Council of India Act**, mandate the preservation of medical records for a minimum of **3 years** from the last date of treatment.
- This regulation falls under the purview of **professional misconduct and medical ethics**, outlining the duties and responsibilities of registered medical practitioners.
*Indian Medical Council (Professional Conduct) Regulations: Medical certificate guidelines*
- While these regulations do describe **medical certificate guidelines**, they do not specifically address the minimum period for preserving general medical records.
- This section focuses on the proper issuance and content of **medical certificates**, not storage duration of patient files.
*Consumer Protection Act: Medical services as consumer services*
- This Act primarily defines **medical services as consumer services** and allows patients to seek redressal for deficiencies in service.
- It does not specify the **duration for medical record preservation** by practitioners but rather grants rights to consumers.
*Section 304A IPC: Death caused by negligence (medical negligence)*
- This section deals with **criminal liability for death caused by negligence**, including medical negligence.
- It is a **penal provision** and does not provide guidelines on the administrative aspect of medical practice, such as record keeping duration.
Drug Development and Regulation Indian Medical PG Question 2: A chemical is tested for carcinogenicity by examining its mutagenic effects on bacterial cells in culture. Which of the following tests is used to make this determination?
- A. Ames test (Correct Answer)
- B. Watson-Schwartz test
- C. Widal test
- D. Nitroblue tetrazolium test
Drug Development and Regulation Explanation: ***Ames test***
- The **Ames test** is a widely used biological assay to assess the **mutagenic potential** of chemical compounds.
- It uses specific strains of bacteria (e.g., *Salmonella typhimurium* or *Escherichia coli*) that have been genetically modified to require a particular nutrient (e.g., histidine) for growth and examines the frequency of **reverse mutations** that allow them to grow without that nutrient, indicating mutagenicity.
*Watson-Schwartz test*
- The **Watson-Schwartz test** is a biochemical test used to detect the presence of **porphobilinogen** in urine, primarily for diagnosing acute intermittent porphyria.
- It is not related to assessing mutagenicity or carcinogenicity.
*Widal test*
- The **Widal test** is a serological test used for the diagnosis of **typhoid fever** by detecting antibodies against *Salmonella typhi* O and H antigens in a patient's serum.
- It is an immunological test and does not assess mutagenic effects.
*Nitroblue tetrazolium test*
- The **Nitroblue tetrazolium (NBT) test** is used to assess the phagocytic function of **neutrophils**, primarily to diagnose **chronic granulomatous disease (CGD)**.
- It measures the ability of neutrophils to produce **superoxide radicals** and is not related to carcinogenicity or mutagenicity.
Drug Development and Regulation Indian Medical PG Question 3: At which phase of a drug trial is permission from the DCGI required?
- A. Phase 1 (Correct Answer)
- B. Phase 2
- C. Phase 3
- D. Phase 4
Drug Development and Regulation Explanation: ***Phase 1***
- **Permission from the Drugs Controller General of India (DCGI)** is **first required** to initiate **Phase 1 clinical trials** in India.
- This permission is obtained through submission of an **Investigational New Drug (IND)** application to DCGI.
- Phase 1 trials involve the **first-in-human** studies to assess **safety, tolerability, pharmacokinetics**, and **pharmacodynamics** in a small group of healthy volunteers or patients.
- **No clinical trial can begin in India without DCGI approval**, making Phase 1 the critical regulatory checkpoint for initial permission.
*Phase 2*
- While Phase 2 trials also require DCGI oversight and approval to proceed from Phase 1, the question asks when permission is **required**, which is at the **initial entry point** (Phase 1).
- Phase 2 focuses on evaluating **efficacy** and further assessing **safety** in a larger group of patients with the target disease.
*Phase 3*
- Phase 3 trials involve large-scale studies to confirm **efficacy**, monitor **adverse reactions**, and compare with standard treatments.
- These trials proceed under the original DCGI approval framework established at Phase 1, with continued regulatory oversight.
*Phase 4*
- Phase 4 trials are **post-marketing surveillance** studies conducted after the drug has received marketing approval.
- These are conducted under different regulatory guidelines for pharmacovigilance and long-term safety monitoring.
Drug Development and Regulation Indian Medical PG Question 4: Which of the following combinations can result in severe toxicity due to inhibition of cytochrome P450 enzymes?
- A. Amiodarone + Atorvastatin
- B. Carbamazepine + Atorvastatin
- C. Atorvastatin + Itraconazole (Correct Answer)
- D. Phenytoin + Atorvastatin
Drug Development and Regulation Explanation: ***Atorvastatin + Itraconazole***
- **Itraconazole** is a potent inhibitor of **CYP3A4**, the primary enzyme responsible for atorvastatin's metabolism.
- Co-administration leads to significantly increased **atorvastatin plasma concentrations**, raising the risk of severe side effects like **rhabdomyolysis** and **hepatotoxicity**.
*Amiodarone + Atorvastatin*
- **Amiodarone** is a moderate **CYP3A4 inhibitor** and can increase atorvastatin levels, but the inhibition is **less potent** than itraconazole.
- While this combination does carry a risk and requires dose adjustment, the interaction is **less severe** compared to the potent inhibition seen with itraconazole.
- The direct CYP inhibition leading to severe atorvastatin toxicity is less pronounced than with itraconazole.
*Carbamazepine + Atorvastatin*
- **Carbamazepine** is a potent **CYP3A4 inducer**, meaning it would increase the metabolism of atorvastatin, potentially *decreasing* its efficacy rather than causing toxicity through inhibition.
- This interaction would typically lead to subtherapeutic atorvastatin levels, rather than severe toxicity.
*Phenytoin + Atorvastatin*
- **Phenytoin** is also a potent **CYP3A4 inducer**, similar to carbamazepine.
- Concurrent use would likely lead to enhanced metabolism and **reduced efficacy of atorvastatin**, not increased toxicity due to enzyme inhibition.
Drug Development and Regulation Indian Medical PG Question 5: From which part of the Papaver somniferum plant does the latex, commonly referred to as 'milk', exude?
- A. Leaf of the plant
- B. Root of the plant
- C. Seeds of the plant
- D. Unripe capsule of the plant (Correct Answer)
Drug Development and Regulation Explanation: ***Unripe capsule of the plant***
- The **latex** (or 'milk') containing **opioid alkaloids** like morphine and codeine is primarily harvested by incising the **unripe seed capsules** of the *Papaver somniferum* plant.
- This milky sap is then collected and dried to produce **crude opium**.
*Leaf of the plant*
- The leaves of *Papaver somniferum* do not contain significant amounts of the latex and are not the primary source of **opium alkaloids**.
- While some **alkaloids** might be present in trace amounts, they are not extracted commercially from the leaves.
*Root of the plant*
- The roots of the poppy plant are not known to exude latex or to be a significant source of medically relevant **opioid alkaloids**.
- Their primary function is absorption of water and nutrients, and anchoring the plant.
*Seeds of the plant*
- While the dried seeds are used for culinary purposes (poppy seeds), they contain very low levels of **opioid alkaloids** compared to the latex.
- The latex is produced within the **capsule** before the seeds fully mature.
Drug Development and Regulation Indian Medical PG Question 6: The following malformation in a baby due to drug intake by mother is classified as \qquad ADR?
- A. Type A
- B. Type D (Correct Answer)
- C. Type E
- D. Type F
Drug Development and Regulation Explanation: ***Type D***
- **Type D** ADRs are **delayed effects** that include **teratogenicity** and **carcinogenicity**, occurring after prolonged exposure or during critical developmental periods.
- The image shows **phocomelia** (severe limb malformation), a classic example of drug-induced teratogenicity (e.g., **thalidomide**), which is classified as a Type D ADR.
*Type A*
- **Type A** ADRs are **augmented** reactions that are predictable, dose-dependent pharmacological effects of drugs.
- Examples include **bleeding** with anticoagulants or **hypotension** with antihypertensives, not congenital malformations.
*Type E*
- **Type E** ADRs are **end-of-use** effects or **withdrawal symptoms** that occur when a drug is discontinued.
- These reactions (like **opioid withdrawal**) are unrelated to developmental malformations from in-utero drug exposure.
*Type F*
- **Type F** is not a recognized category in standard ADR classification systems, which typically include only Types A through E.
- The established classification covers predictable, unpredictable, chronic, delayed, and end-of-use effects without requiring a Type F category.
Drug Development and Regulation Indian Medical PG Question 7: What is the true statement about phase 2 clinical trials?
- A. A large number of healthy volunteers are studied.
- B. Used to determine the maximum tolerated dose.
- C. Used to determine efficacy. (Correct Answer)
- D. Used to determine toxicity.
Drug Development and Regulation Explanation: **Explanation:**
Phase 2 clinical trials are primarily designed to evaluate the **therapeutic efficacy** of a drug in a specific patient population.
1. **Why Option C is Correct:**
Phase 2 trials are often referred to as "Proof of Concept" studies. They are conducted on a relatively small group of patients (typically 100–300) who actually have the target disease. The main goal is to determine if the drug produces the desired clinical effect (efficacy) and to establish the optimal dose-response relationship for larger Phase 3 trials.
2. **Why Other Options are Incorrect:**
* **Option A:** Large numbers of healthy volunteers are not used here. Phase 1 uses a small number (20–100) of healthy volunteers, while Phase 3 uses a large number (1,000–3,000) of patients.
* **Option B:** Determining the **Maximum Tolerated Dose (MTD)** is the primary objective of **Phase 1** trials, where dose-escalation studies are performed to find the safety limit.
* **Option D:** While safety is monitored in all phases, the primary objective of determining **toxicity and safety** profiles in humans is the hallmark of **Phase 1**.
**High-Yield NEET-PG Pearls:**
* **Phase 1:** Safety, Pharmacokinetics, and MTD (Healthy volunteers, except for oncology drugs).
* **Phase 2:** Efficacy and Dose-ranging (Small patient group).
* **Phase 3:** Confirmation of efficacy and safety against a placebo or standard gold treatment (Large multicentric patient group).
* **Phase 4:** Post-marketing surveillance (Detects rare side effects like Phocomelia or Rofecoxib-induced cardiotoxicity).
* **Phase 0:** Microdosing studies to determine human PK parameters before Phase 1.
Drug Development and Regulation Indian Medical PG Question 8: Tachyphylaxis is seen after the use of which of the following drugs?
- A. Tamoxifen
- B. Ephedrine (Correct Answer)
- C. Morphine
- D. Chlorpromazine
Drug Development and Regulation Explanation: **Explanation:**
**Tachyphylaxis** is defined as a rapid decrease in response to a drug after repeated administration over a short period. Unlike tolerance, which develops slowly, tachyphylaxis occurs quickly and cannot be overcome by simply increasing the dose.
**Why Ephedrine is the Correct Answer:**
Ephedrine is a classic example of a drug that exhibits tachyphylaxis. It acts primarily as an **indirect-acting sympathomimetic**, meaning it works by displacing norepinephrine (NE) from storage vesicles in the nerve endings. With repeated, frequent administration, the available stores of NE become depleted. Once the "pool" of neurotransmitters is exhausted, further doses of ephedrine produce little to no pharmacological effect until the nerve endings have time to synthesize and restock NE.
**Analysis of Incorrect Options:**
* **Tamoxifen (A):** This is a Selective Estrogen Receptor Modulator (SERM). It does not typically show rapid desensitization or tachyphylaxis.
* **Morphine (C):** Morphine leads to **Tolerance**, not tachyphylaxis. Tolerance to opioids develops over days or weeks due to receptor downregulation and internalisation, requiring higher doses for the same analgesic effect.
* **Chlorpromazine (D):** This is a typical antipsychotic. While patients may develop tolerance to its sedative effects, it does not exhibit the rapid acute waning of effect characteristic of tachyphylaxis.
**High-Yield Clinical Pearls for NEET-PG:**
* **Common drugs showing Tachyphylaxis:** **T**yramine, **E**phedrine, **A**mphetamine, **N**icotine, **N**itroglycerin, and **D**econgestants (e.g., Xylometazoline). (Mnemonic: **T**ea **E**n**A** **N**i**N**D).
* **Mechanism:** Usually due to depletion of endogenous neurotransmitters or rapid receptor phosphorylation/internalization.
* **Nitrates:** Tachyphylaxis (often called "nitrate tolerance") occurs due to the depletion of free sulfhydryl (-SH) groups required for NO release; hence, a "nitrate-free interval" is recommended.
Drug Development and Regulation Indian Medical PG Question 9: Therapeutic drug monitoring is done for all of the following drugs except?
- A. Phenytoin
- B. Diclofenac (Correct Answer)
- C. Tacrolimus
- D. Cyclosporine
Drug Development and Regulation Explanation: **Explanation:**
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring drug concentrations in the blood to maintain a constant concentration within a specific **therapeutic window**. It is indicated for drugs with a narrow therapeutic index, high inter-individual pharmacokinetic variability, or a direct correlation between plasma levels and clinical effects/toxicity.
**Why Diclofenac is the correct answer:**
Diclofenac is a Non-Steroidal Anti-Inflammatory Drug (NSAID) with a **wide therapeutic index**. Its clinical effect (analgesia and anti-inflammatory action) can be easily monitored by clinical response (reduction in pain or swelling). Furthermore, there is no established correlation between its plasma concentration and its efficacy or toxicity profile, making TDM unnecessary and impractical.
**Analysis of incorrect options:**
* **Phenytoin:** An antiepileptic with **zero-order (saturated) kinetics** at therapeutic doses. Small dose increases can lead to disproportionately large increases in plasma levels, causing toxicity (e.g., ataxia, nystagmus). TDM is mandatory.
* **Tacrolimus & Cyclosporine:** Both are **calcineurin inhibitors** (immunosuppressants) used in organ transplants. They have a very narrow therapeutic window; low levels lead to graft rejection, while high levels cause significant nephrotoxicity and neurotoxicity. TDM is standard of care for these agents.
**High-Yield Clinical Pearls for NEET-PG:**
* **Mnemonic for TDM drugs:** "**L**ithium, **I**mmunosuppressants (Cyclosporine/Tacrolimus), **T**ricyclic Antidepressants, **A**nti-epileptics (Phenytoin/Valproate), **D**igoxin, **A**minoglycosides, **T**heophylline" (**LITA DAT**).
* **Drugs NOT requiring TDM:** Drugs with easily measurable physiological markers (e.g., Warfarin via PT/INR, Antihypertensives via Blood Pressure, Insulin via Blood Glucose).
* **Phenytoin** is a classic "TDM favorite" in exams due to its non-linear pharmacokinetics.
Drug Development and Regulation Indian Medical PG Question 10: Which of the following therapeutic index (T.I.) values represents the greatest safety profile for a drug?
- A. 100
- B. 1,000 (Correct Answer)
- C. 500
- D. 2
Drug Development and Regulation Explanation: ### Explanation
**Concept Overview**
The **Therapeutic Index (T.I.)** is a quantitative measurement of a drug's relative safety [1]. It is defined as the ratio of the dose that produces toxicity to the dose that produces a clinically desired effective response. Mathematically, it is expressed as:
**T.I. = TD₅₀ / ED₅₀** (or LD₅₀ / ED₅₀ in animal studies) [1]
* **TD₅₀:** Toxic dose in 50% of the population.
* **ED₅₀:** Effective dose in 50% of the population.
**Why Option B is Correct**
The safety of a drug is **directly proportional** to its Therapeutic Index [1]. A higher T.I. indicates a wider "margin of safety," meaning there is a large gap between the dose required for efficacy and the dose that causes toxicity [2]. Among the given options, **1,000** is the highest value, representing the widest margin and, therefore, the greatest safety profile.
**Analysis of Incorrect Options**
* **Options A (100) and C (500):** While these values represent relatively safe drugs, they are less safe than a drug with a T.I. of 1,000.
* **Option D (2):** This represents a **Narrow Therapeutic Index (NTI)** drug. Such drugs are inherently risky because a small increase in dose or a minor change in blood concentration can lead to severe toxicity.
**NEET-PG High-Yield Pearls**
* **Narrow Therapeutic Index Drugs (Mnemonic: "W-A-R-F-I-N-G-L-E-T"):** **W**arfarin, **A**minoglycosides/Amiodarone, **R**ifampicin, **F**enytoin (Phenytoin), **I**nsulin, **N**eostigmine, **G**lycosides (Digoxin), **L**ithium, **E**thosuximide/Enalapril, **T**heophylline/Tricyclic Antidepressants.
* **Clinical Monitoring:** Drugs with a low T.I. often require **Therapeutic Drug Monitoring (TDM)** to ensure safety and efficacy [3].
* **Penicillin** is a classic example of a drug with a very high T.I., making it remarkably safe even at high doses.
More Drug Development and Regulation Indian Medical PG questions available in the OnCourse app. Practice MCQs, flashcards, and get detailed explanations.
